Pharmacological Management of Cognitive Decline in an 82-Year-Old Male

Special Considerations for Patient Population Case:

Patient 1: 82-year-old male presenting with cognitive decline. He had always been a very active individual. Over the past year, he has become less active in the community. Previously, he played cribbage weekly with friends at the local senior center but has been struggling with the math involved with the game and no longer attends the weekly card game. He had also volunteered as a crossing guard for the local public school. He quit doing that after he took the wrong turn to get home and drove around the town feeling lost. He acknowledges he is sensitive to this and can be irritable towards his children when they bring up these concerns. He was diagnosed with mild neurocognitive disorder after completing neuropsychological testing. Of the following medications, which would be the most appropriate to prescribe? Explain why you chose this medication. What would be the dosing schedule for this patient? Provide education to the patient and review risks, benefits, and potential side effects of the medication. In addition, explain why the other medications listed are not appropriate for this patient. Med List: lorazepam, olanzapine, memantine

Construct a paper concerning your assigned vulnerable population patient case. In your paper include the following:
Determine which medication would be most appropriate to prescribe from the assigned vulnerable population patient case medication choices.
Explain your rationale for choosing this medication. Explain why the other medications listed are not appropriate for this patient.
Explain the dosing schedule for the specific patient including the therapeutic endpoint.
Provide necessary education to the patient to review risks, benefits, and potential side effects of the medication.
Describe any necessary labs or additional diagnostics needed prior to prescribing this medication.
Explain how you might monitor efficacy or side effects of the medication.
Include any additional collaboration or education to others that would be necessary for this patient. Consider family members, home health care, primary care providers, etc.
What would you need to include in your assessment for a patient who may become nonadherent with your prescribing plan for your scenario? What are alternative treatment solutions based upon how you assessed? Describe your new treatment plan.

Sample Answer

Pharmacological Management of Cognitive Decline in an 82-Year-Old Male

Introduction

Cognitive decline is a significant concern in the elderly population, particularly for individuals diagnosed with neurocognitive disorders. In this case, we examine an 82-year-old male who has been diagnosed with mild neurocognitive disorder and has experienced a decline in his social interactions and daily activities. This paper discusses the most appropriate medication from the provided list, outlines the rationale for its selection, dosing schedule, risks and benefits, and necessary monitoring, while also addressing the appropriateness of alternative medications.

Medication Selection

Most Appropriate Medication: Memantine

Among the medications listed—lorazepam, olanzapine, and memantine—the most suitable choice for this patient is memantine. Memantine is an NMDA receptor antagonist approved for treating moderate to severe Alzheimer’s disease and other forms of dementia. It works by regulating glutamate activity in the brain, which is critical in learning and memory processes, making it appropriate for managing symptoms associated with neurocognitive disorders.

Rationale for Choosing Memantine

1. Targeted Treatment: Memantine specifically addresses cognitive symptoms without sedating effects or exacerbating agitation that may be associated with other medications like lorazepam and olanzapine.
2. Safety Profile: Compared to lorazepam, which is a benzodiazepine associated with increased sedation and risk of falls in the elderly, and olanzapine, which can lead to metabolic side effects and sedation, memantine has a more favorable side effect profile for long-term management.
3. Cognitive Enhancement: Memantine has shown efficacy in improving cognitive function and may slow the progression of symptoms associated with mild neurocognitive disorder.

Inappropriate Medications

– Lorazepam: This benzodiazepine can lead to increased sedation, cognitive impairment, and falls risk, especially in older adults. Its use should be avoided in patients with cognitive decline due to the potential for worsening cognitive function.

– Olanzapine: As an atypical antipsychotic, olanzapine carries risks of significant side effects such as weight gain, metabolic syndrome, sedation, and increased risk of stroke in elderly patients with dementia-related psychosis.

Dosing Schedule

The typical starting dose for memantine is 5 mg once daily, which can be increased to 10 mg once daily after one week based on patient tolerance and clinical response. The maximum recommended dose is 20 mg per day (10 mg twice daily) for optimal therapeutic effect.

Therapeutic Endpoint

The therapeutic endpoint for memantine includes improved cognitive functioning as evidenced by enhanced memory recall, improved social engagement, and reduced irritability. Regular assessments through validated cognitive scales may help gauge efficacy over time.

Patient Education

Risks, Benefits, and Potential Side Effects

1. Benefits:

– Potential improvement in cognitive function and daily living activities.
– May help slow progression of symptoms associated with mild neurocognitive disorder.

2. Risks:

– Possible side effects include dizziness, headache, constipation, confusion, fatigue, and potential cardiovascular issues.

3. Monitoring Side Effects: Patients should be advised to report any unusual symptoms or side effects immediately.

Labs or Additional Diagnostics

Before prescribing memantine, the following evaluations should be conducted:

– Baseline renal function tests: Since memantine is primarily excreted through the kidneys, renal impairment can affect drug clearance.
– Cognitive assessment: To establish a baseline for future comparisons.

Monitoring Efficacy and Side Effects

Monitoring will involve regular follow-up appointments to assess cognitive function and any side effects. Utilizing tools like the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) can help evaluate efficacy over time. Additionally, regular check-ins with family members can provide insight into changes in behavior or cognition.

Collaboration and Education

It’s essential to involve family members in the treatment plan by educating them about memantine’s potential benefits and side effects. They can assist in monitoring the patient’s adherence to the medication regimen and report any changes in mood or behavior to healthcare providers. Coordination with the primary care provider is also crucial for ongoing management.

Addressing Nonadherence

For patients who may become nonadherent to the treatment plan due to cognitive decline or misunderstanding of their condition:

– Simplified Medication Regimen: Ensuring that dosing schedules are straightforward (e.g., once daily) can enhance adherence.
– Pill Organizer: Utilizing pill organizers can help manage doses effectively.
– Regular Check-ins: Scheduled reminders or follow-ups can help keep the patient engaged in their treatment plan.

Alternative Treatment Solutions

If adherence remains an issue or cognitive decline progresses despite treatment:

– Non-pharmacological interventions: Cognitive rehabilitation strategies or engagement in social activities that stimulate cognitive processes should be encouraged.
– Family support programs: Involving family members in support groups or educational sessions about managing cognitive decline can foster a supportive environment.

Revised Treatment Plan

If memantine proves ineffective or if adherence issues persist:

1. Reassess the patient’s cognitive status.
2. Consider introducing structured cognitive therapies or enrolling him in memory-enhancing programs available at local senior centers.
3. Explore community resources or home health services that provide additional oversight and support.

Conclusion

In managing an 82-year-old male patient with mild neurocognitive disorder, memantine represents the most appropriate pharmacological option among those presented. Its targeted action on cognitive symptoms, coupled with a favorable safety profile compared to alternative medications, makes it a suitable choice. Ongoing monitoring and collaborative care involving family and healthcare providers are essential components of the treatment plan to enhance adherence and improve outcomes.

References

1. Salloway, S., et al. (2014). “Memantine for Alzheimer’s disease: A systematic review.” European Journal of Neurology.
2. Saragoussi, D., et al. (2018). “Long-term effectiveness of memantine in Alzheimer’s disease patients.” Alzheimer’s & Dementia.
3. Kales, H.C., et al. (2015). “The role of benzodiazepines in treating older adults.” The American Journal of Geriatric Psychiatry.

This question has been answered.

Get Answer

Subject:
Type:
Pages/Words:
	Single spaced
	approx 275 words per page
Urgency:
Level:
Currency:
Total Cost:

No More Worries!

Paper Formatting

No Lateness!

AEW Guarantees

Pharmacological Management of Cognitive Decline in an 82-Year-Old Male

Sample Answer

This question has been answered.

Compute Cost of Paper

Our Services

Why Choose Us